Vulpes Ventures — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Oxford BioDynamics develops blood-based diagnostic tests built on its EpiSwitch 3D genomics platform, including tests for prostate cancer likelihood (PSE), immune checkpoint inhibitor therapy response (CiRT), and ME/CFS detection.
BiotechDigital HealthMedical DevicesOxford
Alexandre Akoulitchev(Director)David Holbrook(Director)Jon Burrows(Chief Executive Officer)Paul Stockdale(Chief Financial Officer)Matthew Wakefield(Director)
Board seatStephen Diggle· per SEC Form D · $5M raise · filed Nov 2021
Spatial computing company (Series A), based in Melbourne.
Melbourne
Numa Bertron(Director)Zachary Duff(Executive Officer, Director)
Co-investorsAura VenturesInvestible Climate Tech FundRampersand
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.